Sagent Pharmaceuticals (SGNT) announces the approval and launch of its Zoledronic Acid Injection, the generic form of Zometa, in a plastic vial. The U.S. market for Zoledronic Acid Injection is approximately $606M. Additionally, the company says its amended its manufacturing and supply agreement with Actavis (ACT) which provides for an enhanced profit split in favor of SGNT, plus a revised line-up of products and a one-time termination fee of $5 million payable to Sagent.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs